Raysa Morales-Demori, MD, FAAP
- Critical Care
Associate Professor of Pediatrics, Section of Critical Care Medicine, Baylor College of Medicine
Languages: English
Get to know Raysa Morales-Demori, MD, FAAP
The journey that a patient with congenital or acquired heart disease takes is complex and unique. I am humbled to share that journey with you by providing safe and high-quality care. I believe that family/primary care takers play a key role in patient’s clinical progress, for that reason, I make sure that each family understands their child’s condition and listen to care taker’s input.
Clinical Interests
My clinical interest in the management of pulmonary hypertension and/or right ventricular failure in patients with congenital heart disease.
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Baylor College of Medicine | Fellowship | Pediatric Critical Care | 2019 |
| Baylor College of Medicine | Fellowship | Pediatric Cardiology | 2017 |
| Children’s Hospital of the University of Illinois – College of Medicine | Residency | Pediatrics | 2014 |
| Universidad Central de Venezuela – Escuela de Medicina Luis Razetti | Medical School | Doctor of Medicine | 2008 |
Organizations
| Organization Name | Role |
|---|---|
| American Academy of Pediatrics | Member |
| American Academy of Pediatrics Member - Society of Critical Care Medicine | Member |
| Pediatric Cardiac Intensive Care Society | Member |
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Research interests
Pulmonary hypertension; Pediatric Heart failure, Population studies in pediatric cardiology
Morales-Demori R. “Congenital heart disease and cardiac procedural outcomes in patients with trisomy 21 and Turner syndrome”. Congenit Heart Dis 2017 Dec;12(6):820-7.
Morales-Demori R, Jamil O, Serratto M. “Trend of Endurance Level Among Healthy Inner-City Children and Adolescents Over Three Decades”. Pediatric Cardiology 2017 Jan;38(1):123-7.
Rangel, MO., Morales Demori, R., Voll, ST., Wassouf, M., Dick, R., Doukky, R. "Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials". J Nucl Cardiol 2015, Oct; 5(22):1008-18.
Ballany, W., Mansour, K., Morales Demori, R., Al-Amoodi, M., Doukky, R. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: A substudy of the ASSUAGE trial. J Nucl Cardiol 2014, Jun; 21(3):496-502.
Doukky, R., Rangel, MO., Wassouf, M., Dick, R., Alqaid, A., Morales Demori, R. The Safety and Tolerability of Regadenoson in Patients with End-Stage Renal Disease: The First Prospective Evaluation. Journal of Nuclear Cardiology 2013 Apr;20(2):205-13.
Rangel, MO., Morales Demori, R., Doukky, R. Age and Gender as Predictors of Benefit From Aminophylline Administration in Patients Undergoing Regadenoson Stress Myocardial Perfusion Imaging: A Substudy of the ASSUAGE Trial. Am J Ther 2013. Nov-Dec;20(6):622-9.
Doukky, R., Morales Demori, R., Jain, S., Kiriakos, R., Mwansa, V., Calvin, JE. Attenuation of The Side Effect Profile of Regadenoson: A Randomized Double-Blind Placebo-Controlled Study with Aminophylline in Patients Undergoing Myocardial Perfusion Imaging. “THE ASSUAGE TRIAL". Journal of Nuclear Cardiology. 2012 Jun; 19(3):448-57.